Dublin, 16 April 2012 … Biosensia Ltd., a point of care diagnostics Company, will be presenting two posters at this year’s AACC Oak Ridge Conference, ‘Emerging Technologies for 21st Century Clinical Diagnostics’, in San Jose.  The posters will illustrate a series of developments proving the effectiveness of Biosensia’s RapiPlex platform.

RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications including acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care. RapiPlex enables the transition of complex immunoassays from the central laboratory to the point of care across a wide variety of samples types.

The posters: ‘Evaluation of a Multiplex Drugs of Abuse Detection Platform with Integrated Sample Handling Technologies’ and ‘RapiPlex a small volume whole blood quantitative microfluidic fluorescent Point of Care platform’ will describe how Biosensia’s RapiPlex platform can be used to detect drugs of abuse; making it suitable for use in a variety of point of care settings such as hospital ER, doctor’s office, or workplace testing. The ability to detect cardiac markers in blood demonstrates how RapiPlex can be used to rapidly diagnose heart attacks in a clinical setting.

Niamh O’Luanaigh, Head of Assay Development at Biosensia, who led the work and is presenting the posters at the conference said: “The posters show just how powerful RapiPlex is and the significant range of uses for it. We believe that RapiPlex can have a significant impact on the way we currently do test, supporting acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care.”

Diarmuid Flavin, CEO of Biosensia Ltd., said: “This scientific validation of RapiPlex is an important step for us. Having secured funding last year, we are now ready to begin the 510k process for US approval and secure a CE mark for Europe, before moving to full commercialisation in 2013.”

The Oak Ridge Conference is the American Association for Clinical Chemistry’s annual forum for emerging clinical diagnostic technologies and brings together thought leaders from industry, academia, and clinical laboratories. The conference focuses exclusively on pre-commercial technologies.

New funding will see new point of care diagnostic platform technology through to regulatory approval and commercial partnerships

Dublin, 9^th November, 2011: Biosensia, a point of care diagnostics company, has secured Euro 1.2 million investment in its most recent funding round, as part of the company’s plans to advance its regulatory and commercial strategy for its platform in Europe and the US.

The funding round was led by ACT Venture Capital, through its AIB Start-up Accelerator Fund, and included existing investors Seroba BioVentures and Atlantic Bridge.

The funding will be used to secure CE mark and FDA regulatory approval for Biosensia’s products in Europe and the US and advance its commercial partnership strategy. There is a significant unmet need for more convenient, accurate and affordable point of care solutions, and Biosensia is poised to become a major player in the development of next-generation, point of care diagnostic products.

Biosensia’s platform, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications including acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care. RapiPlex enables the transition of complex immunoassays from the central laboratory to the point of care across a wide variety of samples types.

Diarmuid Flavin, CEO of Biosensia, said: “This is an exciting time in Biosensia. Our commercialization plans and technology are progressing rapidly. With this financing, the company can further capitalize on its revolutionary RapiPlex technology. We see a significant market demand across a range of diagnostic applications for our RapiPlex platform.”

“We are delighted to have ACT Venture Capital as a new investor in Biosensia as well as the continued support of Seroba and Atlantic Bridge. We have a great product and this investment will allow us to complete regulatory requirements in the US and Europe, and seek partners to expand into new market opportunities.”

John O’Sullivan, Director at ACT Venture Capital, added: “The RapiPlex platform has huge potential across a broad range of applications, making this a great investment opportunity for ACT. We look forward to working with the Biosensia team as they progress to commercialization.”

Diagnosing a gap in the medical market

.

BIOSENSIA: With healthcare systems worldwide under pressure to tighten their belts, the launch of a fast and cost-effective new diagnostic kit from Irish life sciences company Biosensia is timely.

Biosensia has developed a point-of-care diagnostic system called RapiPlex that can be used by GPs or in hospital settings to take and test patient samples (for example blood or urine) and give a result in minutes. Normally this can take several days if taken by a GP and a number of hours if taken in hospital.

Other innovative aspects of the system that differentiate it from its competitors are that it can analyse up to 12 different aspects of the sample at once and it works with a range of samples from whole blood and serum to plasma and saliva. Most existing tests are specific to one type of sample. The kit comes in two parts – a disposable cartridge for capturing the sample and a bench-top reader that interprets the result of the test.

Biosensia was set up in 2008 to develop a roadside drug-testing kit for use by law- enforcement agencies. Since then the company has changed direction and set its sights on developing a product that would allow it to break into the much broader and potentially more lucrative world of human clinical testing. The value of this market worldwide is estimated to be in excess of $30 billion, according to a 2007 report by Clinica.

While the software driving the multi-patented system is highly complex, the system itself is very easy to use and does not require those operating it to have specialist skills. Biosensia is based at Nova in University College Dublin’s Innovation and Technology Transfer Centre and is now in the final stages of preparing its product for market.

The company employs five people and this is set to rise to 15 as the product nears its commercial launch. It will be launched in the US and Europe simultaneously and it is currently going through the approval process demanded by the US Federal Drugs Authority.

.

Link to original article.

Biosensia Ltd. was recognized as an InterTradeIreland Business Ambassadors for the Dublin at a special event held with Minister Richard Bruton TD, Minister for Jobs, Enterprise and Innovation on Wednesday 1st June in Dublin. Over 80 Ministers, TDs and Senators were also in attendance at the event which recognized SMEs that have excelled through North-South trade and innovation.

Speaking at the event, Diarmuid Flavin, CEO of Biosensia said: “Biosensia first worked with InterTradeIreland’s INNOVA programme in the development of our RapiPlex reader instrument. Intertrade Ireland provided both funding and project support to allow Biosensia accelerate our RapiPlex core product development.” Diarmuid went on to say “I encourage all Irish indigenous SME’s to think globally and act globally to achieve their goals and to seek the assistance of Intertrade Ireland in supporting those goals”

Mr. Richard Bruton TD, Minister for Jobs, Enterprise and Innovation commented, “Government does not create jobs, people and businesses do; and the role of government is to create an environment in which those businesses can prosper. I am determined to do everything I can to reduce costs, improve access to finance and encourage innovation so that good businesses can expand and create the jobs that our economy and society so badly need. If there is one thing Ireland - north and south - does not lack it is enterprising, creative, hardworking people, and I look forward to working with them to discuss what government and small business together can do to get people back to work”.

Over 65 companies from across Ireland attended the event with government representatives, including Ministers of State, TDs and Senators. Local Dublin representatives in attendance on the day included Joe Costello TD, Paschal Donohoe TD, Maureen O’Sullivan TD, Brendan Ryan TD, Terence Flanagan TD, Peter Matthews TD, Olivia Mitchell TD and Senators Catherine Noone and Mary White.

The group of InterTradeIreland Business Ambassadors were also invited to meet President Mary McAleese at an exclusive reception at Áras an Uachtaráin to make their achievements, where she described the companies as ‘Champions of the future and leaders of change.’

.

Senator Martin McAleese, President Mary McAleese, and Biosensia CEO Diarmuid Flavin

Dublin, 14^th March, 2011: Biosensia, the Ireland based Point-of-Care in vitro diagnostics company has been selected to present at the Opening Doors to the NHS Conference in London next week. This full-day conference, organised by Health Enterprise East, will be held on March 16^th at the Radisson Blu Hotel, London Stansted Airport.

OPENING DOORS TO THE NHS CONFERENCE

Health Enterprise East, NHS Innovations East

Through a juried process led by HEE staff, only four companies in total have been chosen to make a presentation at the Opening Doors conference. Biosensia has been selected to present to conference attendees its lead product – a highly innovative, practical and cost-effective point of care platform ‘RapiPlex’.

The Opening Doors to the NHS conference is designed to showcase technologies that are poised to make a dramatic impact on the work of the NHS. This showcase is an ideal way for companies like Biosensia to present products and innovations directly to top healthcare executives in the NHS and to work with the NHS in making the delivery of healthcare more efficient.

“The selection of Biosensia to present at this prestigious conference is exciting” said Diarmuid Flavin, CEO Biosensia. “Biosensia’s innovative technology is aimed at transitioning diagnostic tests traditionally carried out in the central laboratory out into the general medical community improving the quality and effectiveness of point of care testing”.

“The fact that Biosensia has been selected to present at the Conference underscores the importance of our work in developing RapiPlex, Biosensia’s universal point of care platform” said Jim Walsh, Executive Chairman “We look forward to sharing our technology with top healthcare executives in the NHS.”

To find out more about the Conference see http://www.hee.org.uk/Content/Frontpage-Content/Opening-Doors-March-16.html

This full-day London Investor Forum, hosted by Enterprise Ireland, offers investors the opportunity to evaluate over 20 investment opportunities in companies in the Software and Life Sciences sectors.

LONDON INVESTOR FORUM

Jim Walsh, CEO of Biosensia will introduce forum attendees to Biosensia’s lead product – a highly innovative, practical and cost-effective point of care platform ‘RapiPlex’. The technology is available for applications in diverse global diagnostic markets for human and veterinary assays, food safety, and environmental testing.

According to Diarmuid Flavin, COO of Biosensia the company is delighted to be attending the Enterprise Ireland Investor Forum. “Since Biosensia began commercializing its ‘RapiPlex’ platform we’ve seen substantive market demand across a range of diagnostic applications. Our presence at the Investor Forum is a great opportunity for Biosensia as it will afford investors in the UK, and indeed further a field the opportunity to learn more about our company, our technology, and the solutions we offer”.

Investors who would like a private meeting with Biosensia representatives at the forum should contact Diarmuid Flavin at info @ biosensia.com or tel.+353 1 7163650
To find out more about the London Investor Forum being organised by Enterprise Ireland see http://www.enterprise-ireland.com/en/Events/OurEvents/Investor-Forum-2010

.

About Biosensia
Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics. Its latest innovation, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications. With RapiPlex, Biosensia is primed to expand the capabilities of in-vitro diagnostic technologies by balancing innovation which improves turnaround times, specificity and sensitivity with the need to produce cost-effective, user friendly systems.

Biosensia will be presenting and exhibiting at the AACC 2010 (American Association of Clinical Chemistry) Conference at the Anaheim Convention Center, in Anaheim, CA, July 27-29th 2010. The AACC 2010 is the largest clinical laboratory exposition in the world.

Industry Workshop

In addition to exhibiting at the AACC 2010 Biosensia will be presenting at an Industry Workshop in association with Diagnostic Consulting Network and Symbient Product Development on July 28th, 2010 at 7am in the Anaheim Marriott Hotel. This workshop, which is open to all, will focus on the latest technologies for quantitative rapid tests used in diagnostics and will showcase Biosenisa’s highly innovative, practical and cost-effective point of care platform ‘RapiPlex’.

Workshop Title: Practical Development of Quantitative, High Sensitivity Fluorescent Rapid Assay Systems
Presenters: Biosensia, Diagnostic Consulting Network and Symbient Product Development
Location: Anaheim Marriott Hotel
Time and Date: July 28th, 2010 at 7am. Breakfast will be provided.

Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics. Its latest innovation, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications. With RapiPlex, Biosensia is primed to expand the capabilities of in-vitro diagnostic technologies by balancing innovation which improves turnaround times, specificity and sensitivity with the need to produce cost-effective, user friendly systems.

Diarmuid Flavin, Chief Operating Officer of Biosensia will introduce Biosensia’s novel point of care platform ‘RapiPlex’ to conference attendees. Diarmuid has over 15 years’ management experience in the healthcare industry. From diagnostics to medical devices and sterile pharmaceutical manufacture, Diarmuid has experience across a number of sectors and he has worked with a range of companies including Abbott Vascular, Bioniche, and DeRoyal Europe Ltd .

Diarmuid is delighted to be attending the AACC Annual Meeting. According to Diarmuid “Since Biosensia began commercializing its ‘RapiPlex’ platform we’ve seen substantive market demand across a range of diagnostic applications. Our presence at AACC is a great opportunity for Biosensia as it will afford customers, investors, and the general public the opportunity to learn more about our company, our technology, and the solutions we offer”.

Booth Location

Biosensia will be exhibiting at the AACC 2010 Conference at the Anaheim Convention Center, July 27-29. Attendees wishing to meet with Biosensia and learn more about the company, its technology, and the solutions it offers should visit us at booth #1016. If you would like to set up a private meeting time, please contact Diarmuid Flavin at diarmuid.flavin@biosensia.com or +353 1 7163650.

.

AACC Conference Map

Biosensia today announced that it had been awarded a share of InterTradeIreland’s €4 million INNOVA R&D programme.

Biosensia will receive up to €300,000 from cross-border business and development body InterTradeIreland. The funds, awarded through InterTradeIreland’s Innova R&D programme, are designed to reward and encourage ambitious companies on both sides of the border to combine their respective strengths to develop new product offerings and compete on the international stage.

InterTradeIreland Chief Executive Liam Nellis said: “Innova helps companies to work together to develop new products with demonstrable commercial potential and bring them to market faster than if they were working alone. Each application is technically, commercially and financially assessed by a team of experts and the competition is tough. Companies that have made it onto the programme should be very proud of their achievement.”

Under the programme, Dublin-based Biosensia will now collaborate with Marturion Ltd. in Lisburn to develop a next generation point-of-care diagnostic tool which could take testing out of the laboratory and onto hospital wards and bedsides.

Commenting on the collaboration Diarmuid Flavin, COO of Biosensia said “the investment in this R&D project is part of Biosensia’s ongoing commitment to expanding the capabilities of in-vitro diagnostic technologies. We are delighted to have secured InterTradeIreland funding, and look forward to working with Marturian and developing highly innovative and cost-effective point of care instrument technologies.”

Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics. Its latest innovation, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care (POC) in vitro diagnostics platform that gives access to a broad range of diagnostic applications.
.

For further information, please contact info@biosensia.com

Biosensia, the leading point of care in vitro diagnostics company, today announced the launch of a new and comprehensive corporate website. The new site, www.biosensia.com displays the company’s focus on developing innovative point of care technology, in particular its flagship platform technology RapiPlex.

Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics.  Its latest innovation, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care (POC) in vitro diagnostics platform that gives access to a broad range of diagnostic applications.

Biosensia’s Chief Operating Officer, Diarmuid Flavin, said, “Biosensia is proud to announce a completely revised version of our online presence. We trust that the redesigned Biosensia website will enable a better understanding of our growing and changing business activities. The site is easier to navigate and better highlights the intensity of Biosensia’s focus on developing highly innovative and cost-effective point of care technologies.”  “Most important,” added Diarmuid Flavin, “we believe the site now captures our company’s commitment to expanding the capabilities of in-vitro diagnostic technologies by balancing innovation which improves turnaround times, specificity and sensitivity with the need to produce cost-effective, user friendly systems.”

The new site provides a comprehensive description of Biosensia’s novel point of care platform RapiPlex allowing customers, investors, analysts and the general public to better understand the company, its technology, and underlying science.  The Biosensia website will be an important tool for the company to not only support its worldwide marketing efforts on behalf of the RapiPlex technology, but also to communicate important information on how its products could be used and the analytes that can be detected by using the RapiPlex platform.

“The objective of our new website is to create a better, more efficient experience for our customers and prospects” added Diarmuid Flavin. As a result, the new site features a clean and attractive design, a simple but intuitive navigational structure providing easier access to product information.

The website has been redesigned in collaboration with Ireland’s leading online consultancy, Amas and with the support of Enterprise Ireland.